依拉菌素：全球首次获批。

Elsulfavirine: First Global Approval.

机构信息

Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand.

出版信息

Drugs. 2017 Oct;77(16):1811-1816. doi: 10.1007/s40265-017-0820-3.

Abstract

Elsulfavirine (Elpida) is a new-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) being developed by Viriom for the treatment and prevention of human immunodeficiency virus (HIV) infections. It is the prodrug of the active compound VM-1500A, a small molecule selective NNRTI, which prevents HIV replication. In June 2017, elsulfavirine received its first global approval in Russia for the treatment of HIV-1 infections in combination with other antiretroviral medicines. Other formulations of this drug are also being evaluated in preclinical and phase II studies for the treatment of HIV infections and/or pre-exposure and post-exposure prophylaxis. This article summarizes the milestones in the development of elsulfavirine leading to this first approval in HIV-1 treatment.

摘要

埃尔富拉韦（Elpida）是一种新一代非核苷类逆转录酶抑制剂（NNRTI），由 Viriom 公司开发，用于治疗和预防人类免疫缺陷病毒（HIV）感染。它是活性化合物 VM-1500A 的前药，VM-1500A 是一种小分子选择性 NNRTI，可阻止 HIV 复制。2017 年 6 月，埃尔富拉韦在俄罗斯获得首个全球批准，与其他抗逆转录病毒药物联合用于治疗 HIV-1 感染。该药的其他制剂也正在进行临床前和 II 期研究，用于治疗 HIV 感染和/或暴露前和暴露后预防。本文总结了埃尔富拉韦开发过程中的里程碑事件，这些事件导致了该药在 HIV-1 治疗方面的首次批准。